As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
→ The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
→ The submission file is in OpenOffice, Microsoft Word, or RTF document file format.
→ Where available, URLs for the references have been provided.
→ The text is single-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and all illustrations, figures, and tables are placed within the text at the appropriate points, rather than at the end.
→ The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines.
Please visit journal submission page to submit manuscript for peer review.
Submission page link: https://jagriculture.com/index.php/AJRRA/submission
Artificial intelligence
These guidelines cover acceptable uses of generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators in the writing or editing of manuscripts.
AI use by authors
Authors should not list a generative AI technology as a co-author or author of any submitted manuscript. Generative AI technologies cannot be held accountable for all aspects of a manuscript and consequently do not meet the criteria required for authorship.
If the author of a submitted manuscript has used written or visual content produced by or edited using a generative AI technology, this use must follow publication guidelines and policies. Specifically, the author is responsible for checking the factual accuracy of any content created by the generative AI technology. This includes, but is not limited to, any quotes, citations or references. Figures produced by or edited using a generative AI technology must be checked to ensure they accurately reflect the data presented in the manuscript. Authors must also check that any written or visual content produced by or edited using a generative AI technology is free from plagiarism.
If the author of a submitted manuscript has used written or visual content produced by or edited using a generative AI technology, such use must be acknowledged in the acknowledgements section of the manuscript and the methods section if applicable. This explanation must list the name, version, model, and source of the generative AI technology. We encourage authors to upload all input prompts provided to a generative AI technology and outputs received from a generative AI technology in the supplementary files for the manuscript.
The following section provides a polished overview of common paper categories, including their purpose, scope, and recommended length or supporting materials where applicable.
1. Original Research Papers
Original research papers present unpublished empirical data, except for material previously presented as an abstract. Null or negative findings, replication studies, and refutation studies are also welcome. These papers should normally not exceed 25 double-spaced pages, including references, and should include no more than 15 figures and/or tables.
2. Short Research Articles
Short Research Articles, also known as Research Notes, report a single finding. They should usually be supported by one or two illustrations, such as figures or tables, and may include laboratory protocols. Posters presented at conferences or internal meetings may be developed into Short Research Articles. In many cases, additional detail may be required in the methods, results, and/or discussion and conclusions so that readers and reviewers can fully understand the work. A typical submission should include 3-4 figures and/or tables and 15-20 key references.
3. Short Communications
Short Communications report urgent, important preliminary findings that are highly original, of broad interest, and likely to have a significant impact on the journal's subject area. A Short Communication needs only to establish proof of principle. Authors are encouraged to submit a full Original Research Paper to the journal after publication of a Short Communication. There is no strict page limit; however, 2-3 figures and/or tables and 15-20 key references are recommended.
4. Review Papers
Review papers do not present new empirical data generated by the authors. Instead, they critically discuss, synthesize, and interpret published research and previously acquired data within a specific subject area.
5. Minireview Papers
Minireviews are concise historical perspectives or summaries of developments in fast-moving areas within the scope of the journal. They must be based on published articles and should not be used to present unpublished data. A Minireview may address any relevant subject within the journal's scope. Its purpose is to provide a clear and concise summary of a particular field in a way that is understandable to all readers.
6. Systematic Reviews
Systematic Reviews, particularly in biomedical journals, are usually based on medical interventions or animal-model studies. Authors are advised to consult the PRISMA guidelines when preparing a Systematic Review. These papers should address a clearly formulated research question and use systematic, explicit methods to identify, select, and critically assess relevant studies.
7. Policy Papers
Policy Papers provide a comprehensive and persuasive argument in support of specific policy recommendations. Their purpose is to serve as a decision-making tool and a call to action for the target audience. The recommended length is 3,000-4,000 words, supported by 3-4 figures and/or tables and 15-20 key references.
8. Commentaries / Opinion Articles
Commentaries or Opinion Articles present an opinion-based discussion of a topical issue of broad interest and are intended to encourage debate and discussion. The recommended length is 2,500-3,500 words, supported by 2-3 figures and/or tables and 15-20 key references.
9. Data Notes
Data Notes are brief descriptions of scientific datasets. They explain why and how the data were created but do not include analyses, results, or conclusions.
10. Study Protocols and Pre-protocols
Study Protocols, commonly used in biomedical journals, may be submitted for any study design, including observational studies and systematic reviews. Protocols for randomized clinical trials must be registered and should follow the CONSORT guidelines. Ethical approval must already have been granted before submission. Study pre-protocols, which discuss provisional study designs, may also be submitted and will be clearly labeled as such when published. Protocols for pilot and feasibility studies may also be considered.
11. Method Articles
Method Articles describe a new experimental or computational method, test, or procedure that has been thoroughly tested. They may also describe substantive modifications to existing methods or innovative applications of existing methods to new models or scientific questions. The journal also welcomes technical tools that support experimental design, data analysis, laboratory work, or medical treatment, such as software, laboratory devices, and drug-delivery technologies. The recommended length is 3,000-4,000 words, supported by 3-4 figures and/or tables and 15-20 key references.
12. Data Articles
Data Articles, mainly used in biomedical journals, present a dataset or a set of datasets together with the methods or protocols used to create them. They should not include data analysis, results, or conclusions.
13. Case Reports / Case Studies
Case Reports, mainly used in biomedical journals, describe patient cases that are notable because of their originality, novelty, or clinical relevance. Originality and clinical implications are the main qualities by which Case Reports are evaluated. Case Studies provide valuable records of clinical practice and can help frame questions for more rigorous clinical studies. They also serve as useful teaching material by demonstrating both typical and unusual clinical presentations. The abstract for a Case Report should not exceed 250 words and should include the following sections: Aims, Presentation of Case, Discussion, and Conclusion. Case Reports should not exceed 2,000 words, 20 references, or 5 figures. For more information please consult NCBI PubMed record 18677298 and PMC article PMC2597880.
14. Clinical Practice Articles
Clinical Practice Articles, mainly used in biomedical journals, are short articles focused on a specific clinical problem or scenario. They discuss patient management and treatment pathways using an evidence-based approach. These articles may include case series, meaning groups or series of case reports involving patients who received similar treatment, but they should not be based on a single case.
15. Grey Literature Government Reports
A special section of the journal may be dedicated to publishing extended abstracts of grey literature government reports. Many governmental research institutes produce high-quality scientific reports for government sponsors, but these reports are often available only on institutional websites and are not easily identified through standard literature-searching systems. As a result, valuable scientific work may remain unnoticed by the wider research community, leading to possible duplication of work, loss of resources, and slower scientific progress. To address this issue, the journal may publish extended abstracts of strong governmental reports through the regular peer-review process. Scientific excellence, open access, and English-language availability are the key prerequisites. Once accepted, the extended abstract should include the title of the work, the authors, and a hyperlink to the original full scientific report. This approach helps make government research more visible to a global scientific audience and allows the authors to disseminate their findings more widely.
Reference and more information:
1. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2647072
2. http://www.nejm.org/page/author-center/letter-submission
3. http://www.sciencemag.org/site/misc/editor.xhtml
Papers must be submitted on the understanding that they have not been published elsewhere and are not currently under consideration by another journal published by this publisher or any other publisher. The submitting author is responsible for ensuring that the article's publication has been approved by all the other coauthors. It is also the authors' responsibility to ensure that the articles emanating from a particular institution are submitted with the approval of the necessary institution. Only an acknowledgement from the editorial office officially establishes the date of receipt. Further correspondence and proofs will be sent to the author(s) before publication unless otherwise indicated. It is a condition of submission of a paper that the authors permit editing of the paper for readability. All inquiries concerning the publication of accepted papers should be addressed to [email protected]
Please see here
Please see here
Units of measurement should be presented simply and concisely using System International (SI) units.
The following information should be included
Paper title
Full author names
Full institutional mailing addresses
Email addresses of all authors
The manuscript should be written in English with a simple layout. The text should be prepared in single column format. The text, excluding the abstract, if required, can be divided into numbered sections with brief headings. Starting from the introduction with section 1, subsections should be numbered (for example 2.1 (then 2.1.1, 2.1.2, 2.2, etc.), up to three levels
Title
The title should be without any abbreviations and it should enlighten the contents of the paper.
Abstract
The abstract should be concise and informative. It should not exceed 300 words in length. It should briefly describe the purpose of the work, techniques, and methods used, major findings with important data and conclusions. Different sub-sections, as given below, should be used. No references should be cited in this part. Generally, non-standard abbreviations should not be used, if necessary they should be clearly defined in the abstract, at first use.
Keywords
Immediately after the abstract, about 4-8 keywords should be given. Use of abbreviations should be avoided, only standard abbreviations, well known in the established area may be used, if appropriate. These keywords will be used for indexing.
Abbreviations
Non-standard abbreviations should be listed and full form of each abbreviation should be given in parentheses at first use in the text.
Introduction
Provide a factual background, clearly defined problem, proposed solution, a brief literature survey and the scope and justification of the work done.
Material and methods
Give adequate information to allow the experiment to be reproduced. Already published methods should be mentioned with references. Significant modifications of published methods and new methods should be described in detail. This section will include sub-sections. Tables & figures should be placed inside the text. Tables and figures should be presented as per their appearance in the text. It is suggested that the discussion about the tables and figures should appear in the text before the appearance of the respective tables and figures. No tables or figures should be given without discussion or reference inside the text.
Tables should be explanatory enough to be understandable without any text reference. Double spacing should be maintained throughout the table, including table headings and footnotes. Table headings should be placed above the table. Footnotes should be placed below the table with superscript lowercase letters.
Each figure should have a caption. The caption should be concise and typed separately, not in the figure area. Figures should be self-explanatory. Information presented in the figure should not be repeated in the table. All symbols and abbreviations used in the illustrations should be defined clearly. Figure legends should be given below the figures.
Some guidelines for Medical papers:
Randomized controlled trials should follow the CONSORT (Consolidated Standards of Reporting Trials) guidelines (http://www.consort-statement.org).
Case reports, case series, cross-sectional and other observational studies should follow the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines (http://www.strobe-statement.org). If the detailed methods are explicitly stated in the manuscript for single case studies, STROBE may be avoided.
Authors producing systematic reviews and meta-analyses should follow the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (http://www.prisma-statement.org).
Results & Discussion
Results should be clearly described in a concise manner. Results for different parameters should be described under subheadings or in a separate paragraph. Table or figure numbers should be mentioned in parentheses for better understanding.
The discussion should not repeat the results, but provide a detailed interpretation of data. This should interpret the significance of the findings of the work. Citations should be given in support of the findings. The results and discussion part can also be described as separate, if appropriate.
Tables & Figures
Tables & figures should be placed inside the text. Tables and figures should be presented as per their appearance in the text. It is suggested that the discussion about the tables and figures should appear in the text before the appearance of the respective tables and figures. No tables or figures should be given without discussion or reference inside the text.
Tables should be explanatory enough to be understandable without any text reference. Double spacing should be maintained throughout the table, including table headings and footnotes. Table headings should be placed on the table. Footnotes should be placed below the table with superscript lowercase letters. Vertical rules should not be used.
Each figure should have a caption. The caption should be concise and typed separately, not in the figure area. Figures should be self-explanatory. Information presented in the figure should not be repeated in the table. All symbols and abbreviations used in the illustrations should be defined clearly. Figure legends should be given below the figures. Upon submission of an article, authors are supposed to include all figures and tables in the PDF file of the manuscript. Figures and tables should not be submitted in separate files. If the article is accepted, authors will be asked to provide the source files of the figures. Each figure should be supplied in a separate electronic file. All figures should be cited in the paper in a consecutive order. Figures should be supplied in either vector art formats (Illustrator, EPS, WMF, FreeHand, CorelDraw, PowerPoint, Excel, etc.) or bitmap formats (Photoshop, TIFF, GIF, JPEG, etc.). Bitmap images should be of 300 dpi resolution at least
Guideline for Reporting P values:
P is always italicized and capitalized.
i) Correct expression: (P = .05). Wrong Expression: (P < .05), unless P < .001.
ii) The P value should be expressed to 2 digits whether or not it is significant. If P < .01, it should be expressed to 3 digits.
iii) When rounding, 3 digits is acceptable if rounding would change the significance of a value (eg, P = .049 rounded to .05).
iv) Expressing P to more than 3 significant digits does not add useful information since precise P values with extreme results are sensitive to biases or departures from the statistical model.
v) Reporting actual P values avoids this problem of interpretation. P values should not be listed as not significant (NS) since, for meta-analysis, the actual values are important and not providing exact P values is a form of incomplete reporting.
vi) Do not use 0 before the decimal point for statistical values P, alpha, and beta because they cannot equal 1.
Conclusions
This should briefly state the major findings of the study.
Acknowledgments
A brief acknowledgement section may be given after the conclusion section just before the references. The acknowledgements of people who provided assistance in manuscript preparation, funding for research, etc. should be listed in this section. All sources of funding should be declared as an acknowledgement. Authors should declare the role of the funding agency, if any, in the study design, collection, analysis, and interpretation of data; in the writing of the manuscript. If the study sponsors had no such involvement, the authors should so state.
Competing Interests
Declaration of competing interest should be placed here. All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately (or appropriately) influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If no such declaration has been made by the authors, this journal reserves to assume and write this sentence: “Authors have declared that no competing interests exist.”.
Authors’ Contributions
Authors may use the following wording for this section: “ ‘Author A’ designed the study, performed the statistical analysis, wrote the protocol, and wrote the first draft of the manuscript. ‘Author B’ and ‘Author C’ managed the analyses of the study. ‘Author C’ managed the literature searches…… All authors read and approved the final manuscript.”
Consent
No manuscripts will be peer-reviewed if a statement of patient consent is not presented during submission (wherever applicable).
This section is compulsory for medical journals. Other journals may require this section if found suitable. It should provide a statement to confirm that the patient has given their informed consent for the case report to be published. Journal editorial office may ask the copies of the consent documentation at any time.
Authors may use a form from their own institution or this Patient Consent Form. It is preferable that authors should send this form along with the submission. But if already not sent during submission, we may request to see a copy at any stages of pre and post-publication.
If the person described in the case report has died, then consent for publication must be collected from their next of kin. If the individual described in the case report is a minor, or unable to provide consent, then consent must be sought from their parents or legal guardians.
Authors may use the following wording for this section: "All authors declare that ‘written informed consent was obtained from the patient (or other approved parties) for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editorial office/Chief Editor/Editorial Board members of this journal."
Ethical Approval
This section is compulsory for medical journals. Other journals may require this section if found suitable. If human subjects are involved, informed consent, protection of privacy, and other human rights are further criteria against which the manuscript will be judged. It should provide a statement to confirm that the authors have obtained all necessary ethical approval from suitable Institutional or State or National or International Committee. This confirms either that this study is not against the public interest, or that the release of information is allowed by legislation.
All manuscripts which deal with animal subjects must be approved by an Institutional Review Board (IRB), Ethical Committee, or an Animal Utilization Study Committee. , and this statement, and approval number must accompany the submission. If required, the author should be ready to submit a scanned copy of the IRB or Ethical Committee Approval at any stage of publication (Pre or post-publication stage). The manuscript should contain information about any post-operative care and pain management for the animals.
For manuscripts involving animal experiments, Authors may use the following wording for this section “All authors hereby declare that "Principles of laboratory animal care" (NIH publication No. 85-23, revised 1985) were followed, as well as specific national laws where applicable. All experiments have been examined and approved by the appropriate ethics committee”
All manuscripts which deal with the study of human subjects must be accompanied by Institutional Review Board (IRB) or Ethical Committee Approval, or the national or regional equivalent. The name of the Board or Committee giving approval and the study number assigned must accompany the submission. If required, the author should be ready to submit a scanned copy of the IRB or Ethical Committee Approval at any stage of publication (Pre or post-publication stage).
For manuscripts involving human experiments, Authors may use the following wording for this section: “All authors hereby declare that all experiments have been examined and approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.”
Reference Style
References must be listed at the end of the manuscript. Every source cited in the text must appear in the reference list, and every reference included in the reference list must be cited in the text. In-text citations should follow the format: (Author, Year).
The APA reference style must be followed throughout the manuscript. In the reference list, all references should include a DOI in the format https://doi.org/10... wherever available. If a DOI is not available, a stable web link should be provided instead.
Only published or accepted manuscripts should be included in the reference list. Articles submitted for publication, unpublished findings and personal communications should not be included in the reference list but may be mentioned in the text (e.g., T Nelson, Purdue University, USA, Unpublished results or personal communication). Avoid citing a “personal communication” unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in parentheses in the text. For scientific articles, obtain written permission and confirmation of accuracy from the source of a personal communication. Unpublished result which has been accepted for publication in any journal should be cited as "in press". Journal name abbreviations should be those found in the NCBI databases
(Link: http://www.ncbi.nlm.nih.gov/nlmcatalog/journals).
Recommendation to fight against Reference manipulation or Citation of improper References
As per our policy to protect the journal from the problem of reference manipulation or citation of improper references, we strongly discourage grouping of more than 5 references after a single sentence. Authors are requested to mention maximum of 5 references after a single sentence within the manuscript. This will also improve the readability of the published paper.
Note: This journal will follow this new reference style, effective from 7 January, 2025.
All references should follow the following style:
Reference to a journal:
For Published paper:
1. Hilly, M., Adams, M. L., & Nelson, S. C. (2002). A study of digit fusion in the mouse embryo. Clinical and Experimental Allergy, 32(4), 489-498.
Note: List the first six authors followed by et al.
Note: Use of a DOI number for the full-text article is encouraged. (if available).
Note: Authors are also encouraged to add other database's unique identifier (like PUBMED ID).
For Accepted, unpublished papers.
Same as above, but “In press” appears instead of the page numbers.
1. Saha, M., Adams, M. L., & Nelson, S. C. (2009). Review of digit fusion in the mouse embryo. Journal of Embryology and Experimental Morphology, 49(3), (In press).
Note: List the first six authors followed by et al.
Note: Use of a DOI number is encouraged (if available).
Note: Authors are also encouraged to add other database's unique identifier (like PUBMED ID).
For Articles not in English
Forneau, E., & Bovet, D. (1933). Recherches sur l'action sympathicolytique d'un nouveau dérivé du dioxane. Archives Internationales de Pharmacodynamie, 46, 178-191.
Reference to a book:
Personal author(s)
Rang, H. P., Dale, M. M., Ritter, J. M., & Moore, P. K. (2003). Pharmacology (5th ed.). Edinburgh: Churchill Livingstone.
Editor(s) or compiler(s) as authors
Beers, M. H., Porter, R. S., Jones, T. V., Kaplan, J. L., & Berkwits, M. (Eds.). (2006). The Merck manual of diagnosis and therapy (18th ed.). Merck Research Laboratories.
Authored chapter in edited publication
Glennon, R. A., & Dukat, M. (2002). Serotonin receptors and drugs affecting serotonergic neurotransmission. In D. A. Williams & T. L. Lemke (Eds.), Foye's principles of medicinal chemistry (5th ed., pp. xx-xx). Philadelphia: Lippincott Williams & Wilkins.
Reference to Web-resource or Electronic articles.
Hugo, J. T., & Mondal, S. C. (2006). Parallels between tissue repair and embryo morphogenesis: A conceptual framework. Global Health, 16, 4. https://doi.org/10.1186/1744-8603-1-14
Anonymous. (2006). Parallels between tissue repair and embryo morphogenesis: A conceptual framework. Globalization and Health, 16(4). http://www.globalizationandhealth.com/content/1/1/14
Reference to Organization as author
Diabetes Prevention Program Research Group. (2009). A study of digit fusion in the mouse embryo. Journal of Embryology and Experimental Morphology, 49(2), 259–276.
A PDF file of proof will be sent to the corresponding author as an e-mail attachment. Authors will be asked to check any typographical or minor clerical errors in the manuscript at this stage. No other major alteration in the manuscript is allowed.
Authors are requested to visit Journal Price Page to have more information.
Up to 31 December, 2023 transfer of copyright from the author(s) to the publisher was mandatory. From the beginning of 2024, there is no need for copyright transfer to the publisher. From 2024 the author(s) retain the copyright of the respective paper. In this case author(s) grants a perpetual license to publish the paper to the publisher, whereas the original copyright remains with the author(s). From, 2024 all papers are published with Creative Commons ( CC-BY 4.0) license.
Authors cannot submit a manuscript for publication to other journals simultaneously. It is waste of valuable resources because editors and referees spent a great deal of time processing submitted manuscripts. It is also unethical to republish similar research articles (text/figures/tables) again because journals have limited page space and it most likely violates copyrights which have already been transferred to the first journal. Therefore, all journals require a signed author's copyright transfer agreement stating the originality of the research work submitted through a manuscript. As stated above that authors should submit original, new and unpublished research work to the journal. The ethical issues such as plagiarism, fraudulent and duplicate publication, violation of copyrights, authorship and conflict of interest are serious issues concerning ethical integrity when submitting a manuscript to a journal for publication.
If the author requests withdrawal of manuscript after submission within the time span when the manuscript is still in the peer-reviewing process with Editors/Referees, an author is allowed to withdraw the manuscript without paying any withdrawal penalty whatsoever. However, it is unethical to withdraw a submitted manuscript from one journal if accepted by another journal. The withdrawal of manuscripts from the journals after submitting to the publisher will incur a withdrawal penalty. After the manuscript is accepted for publication either through journal editors or guest editors, the withdrawal is not permitted. If the authors or conference organizers or a third party withdraw manuscripts any time after final manuscripts have already been submitted to this journal for processing, the request is not entertained without a significant withdrawal penalty. Authors or conference organizers or a third party are not allowed to withdraw submitted manuscripts because the withdrawal wastes valuable manuscript processing time, money and works invested by the publisher. The authors or conference organizers or a third party must always pay $200 per page manuscript processing charges as withdrawal penalty to the publisher even if the withdrawal is permitted. The withdrawal of the conference papers by conference organizers will never be permitted and the conference organizers will be punished for withdrawal by paying a withdrawal penalty of US$500 per manuscript. Withdrawal of manuscripts is only allowed after withdrawal penalty has been fully paid to this journal by the authors or conference organizers or a third party. Any reason whatsoever of withdrawal of submitted manuscripts is treated as invalid and completely unacceptable under any circumstances. Publisher is not responsible for any damages whatsoever resulting from this consequence of the author's or conference organizer's or a third party decision. All questions or differences whatsoever concerning manuscripts withdrawal from this journal whether as to construction or otherwise, shall be held in the local jurisdiction of the registered editorial office of this journal.
Publication Ethics and Malpractice Statement
Ethical standards
Ethical standards for publication exist to ensure high-quality scientific publications, public trust in scientific findings, and that people receive credit for their ideas. This journal abides by Code of Conduct of Committee on Publication Ethics (COPE) and aims to adhere to its Best Practice Guidelines.
Plagiarism
All journals published by this journal are committed to publishing only original material, i.e., material that has neither been published elsewhere, nor is under review elsewhere. Manuscripts that are found to have been plagiarized from a manuscript by other authors, whether published or unpublished, will incur plagiarism sanctions.
Duplicate Submission
Manuscripts that are found to have been published elsewhere, or to be under review elsewhere, will incur duplicate submission/publication sanctions. If authors have used their own previously published work, or work that is currently under review, as the basis for a submitted manuscript, they are required to cite the previous work and indicate how their submitted manuscript offers novel contributions beyond those of the previous work.
Citation Manipulation
Submitted manuscripts that are found to include citations whose primary purpose is to increase the number of citations to a given author’s work, or to articles published in a particular journal, will incur citation manipulation sanctions.
Data Fabrication and Falsification
Submitted manuscripts that are found to have either fabricated or falsified experimental results, including the manipulation of images, will incur data fabrication and falsification sanctions.
Improper Author Contribution or Attribution
All listed authors must have made a significant scientific contribution to the research in the manuscript and approved all its claims. It is important to list everyone who made a significant scientific contribution, including students and laboratory technicians.
Redundant Publications
Redundant publications involve the inappropriate division of study outcomes into several articles.
Sanctions
In the event that there are documented violations of any of the above mentioned policies in any journal, regardless of whether or not the violations occurred in a journal published by this journal, the following sanctions will be applied:
* Immediate rejection of the infringing manuscript.
* Immediate rejection of every other manuscript submitted to any journal published by this journal by any of the authors of the infringing manuscript.
* Prohibition against all of the authors for any new submissions to this journal, either individually or in combination with other authors of the infringing manuscript, as well as in combination with any other authors. This prohibition will be imposed for a minimum of 24 months.
* Prohibition against all of the authors from serving on the Editorial Board of this journal.
In cases where the violations of the above policies are found to be particularly egregious, the publisher reserves the right to impose additional sanctions beyond those described above.